ALXN 2040, Placebo matching ALXN2040
ALXN2040-GA-201
Phase 2 small_molecule active
Quick answer
ALXN 2040, Placebo matching ALXN2040 for Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD) is a Phase 2 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alexion Europe SAS
- Indication
- Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active